Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Our proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. Our highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Total Funding: $107.3 M
Funding Stage: Series D
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2015
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Ultivue
Senior Scientist, Research
Cambridge, Massachusetts
Research Scientist
Cambridge, Massachusetts
Associate Scientist, Research
Cambridge, Massachusetts
Associate Scientist, Research
Cambridge, Massachusetts
Senior Director, Computational Pathology
Cambridge, Massachusetts